Looking Back: Ovarian Cancer in 2017

Video

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on exciting developments in the ovarian cancer field from 2017. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes these drugs have great potential in ovarian cancer treatment.

Related Videos
Related Content
FDA Approval of Oncology Drugs in March 2024

FDA Approval of Oncology Drugs in March 2024

April 1st 2024
Article

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

FDA Approves Onbody Administration System for Pegfigrastim Biosimilar

FDA Approves Onbody Administration System for Pegfigrastim Biosimilar

January 6th 2024
Article

The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

FDA

The FDA is Considering Granting Regular Approval to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

December 13th 2023
Article

The FDA has granted priority review to mirvetuximab soravtansine for folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Cervical Cancer

Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial

December 3rd 2023
Article

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.

© 2024 MJH Life Sciences

All rights reserved.